STERIALS

A biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders for which no effective treatment exists. The product candidate, tildacerfont, is a non-steroidal therapy being developed to improve disease control and reduce steroid burden in adult and pediatric patients suffering from classical congenital adrenal hyperplasia, and for the treatment of polycystic ovary syndrome. Delaware-based